![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZBED6CL |
Gene summary for ZBED6CL |
![]() |
Gene information | Species | Human | Gene symbol | ZBED6CL | Gene ID | 113763 |
Gene name | ZBED6 C-terminal like | |
Gene Alias | C7orf29 | |
Cytomap | 7q36.1 | |
Gene Type | protein-coding | GO ID | NA | UniProtAcc | A0A090N8P6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
113763 | ZBED6CL | HCC1_Meng | Human | Liver | HCC | 1.41e-26 | 4.45e-02 | 0.0246 |
113763 | ZBED6CL | HCC2 | Human | Liver | HCC | 1.07e-02 | 1.69e+00 | 0.5341 |
113763 | ZBED6CL | S014 | Human | Liver | HCC | 2.03e-14 | 5.58e-01 | 0.2254 |
113763 | ZBED6CL | S015 | Human | Liver | HCC | 2.39e-18 | 5.51e-01 | 0.2375 |
113763 | ZBED6CL | S016 | Human | Liver | HCC | 1.23e-12 | 4.01e-01 | 0.2243 |
113763 | ZBED6CL | S028 | Human | Liver | HCC | 4.65e-12 | 3.82e-01 | 0.2503 |
113763 | ZBED6CL | S029 | Human | Liver | HCC | 6.01e-08 | 2.88e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | ![]() |
Stomach | SIM | ![]() |
Liver | NAFLD | ![]() |
Liver | Cirrhotic | ![]() |
Liver | HCC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZBED6CL | SNV | Missense_Mutation | novel | c.475G>T | p.Ala159Ser | p.A159S | Q96FA7 | protein_coding | tolerated(1) | benign(0.003) | TCGA-E9-A226-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
ZBED6CL | insertion | Frame_Shift_Ins | novel | c.193_194insATGGTGAAATCCCG | p.Leu65HisfsTer48 | p.L65Hfs*48 | Q96FA7 | protein_coding | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
ZBED6CL | deletion | Frame_Shift_Del | novel | c.534_538delNNNNN | p.Glu179LysfsTer24 | p.E179Kfs*24 | Q96FA7 | protein_coding | TCGA-AC-A3W7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD | ||
ZBED6CL | SNV | Missense_Mutation | c.428A>T | p.Glu143Val | p.E143V | Q96FA7 | protein_coding | deleterious(0.05) | benign(0.082) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
ZBED6CL | SNV | Missense_Mutation | novel | c.593A>C | p.Lys198Thr | p.K198T | Q96FA7 | protein_coding | deleterious(0.04) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZBED6CL | SNV | Missense_Mutation | rs776445212 | c.11N>A | p.Arg4His | p.R4H | Q96FA7 | protein_coding | tolerated(0.1) | benign(0.001) | TCGA-AA-3666-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
ZBED6CL | SNV | Missense_Mutation | rs756908891 | c.203G>A | p.Arg68His | p.R68H | Q96FA7 | protein_coding | tolerated(0.19) | benign(0.011) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
ZBED6CL | SNV | Missense_Mutation | c.428N>C | p.Glu143Ala | p.E143A | Q96FA7 | protein_coding | tolerated(0.36) | benign(0.001) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ZBED6CL | SNV | Missense_Mutation | rs370437244 | c.616N>A | p.Val206Ile | p.V206I | Q96FA7 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AG-3881-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZBED6CL | SNV | Missense_Mutation | c.115N>A | p.Val39Ile | p.V39I | Q96FA7 | protein_coding | tolerated(0.27) | benign(0.001) | TCGA-AG-3887-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | irinotecan | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |